Patents by Inventor Steven A. Rosenberg

Steven A. Rosenberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240082307
    Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes methods of identifying a patient who would respond well to a T cell therapy or conditioning a patient prior to a T cell therapy so that the patient responds well to a T cell therapy. The conditioning involves administering one or more preconditioning agents prior to a T cell therapy and identifying biomarker cytokines prior to administering a T cell therapy.
    Type: Application
    Filed: August 24, 2023
    Publication date: March 14, 2024
    Applicants: Kite Pharma, Inc., Ofc of Tech Transfer, NIH
    Inventors: Adrian BOT, Jeffrey S. WIEZOREK, William GO, Rajul JAIN, James N. KOCHENDERFER, Steven A. ROSENBERG
  • Patent number: 11925664
    Abstract: Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: March 12, 2024
    Assignees: INTIMA BIOSCIENCE, INC., REGENTS OF THE UNIVERSITY OF MINNESOTA, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Branden Moriarity, Beau Webber, David Largaespada, Modassir Choudhry, Steven A. Rosenberg
  • Patent number: 11923065
    Abstract: Computer-implemented systems, computer-implemented methods, and tangible, non-transitory computer-readable media for detecting abnormal heart rhythms of a user performing treatment plan with an electromechanical machine. The system includes, in one embodiment, an electromechanical machine, one or more sensors, and one or more processing devices. The electromechanical machine is configured to be manipulated by a user while the user is performing a treatment plan. The one or more sensors are configured to determine one or more measurements associated with the user. The one or more processing devices are configured to receive, from the one or more sensors while the user performs the treatment plan, the one or more measurements associated with the user. The one or more processing devices also configured to determine, using one or more machine learning models, a probability that the one or more measurements indicate that the user satisfies a threshold for a condition associated with an abnormal heart rhythm.
    Type: Grant
    Filed: June 30, 2023
    Date of Patent: March 5, 2024
    Assignee: ROM Technologies, Inc.
    Inventors: Joel Rosenberg, Steven Mason
  • Patent number: 11918640
    Abstract: Disclosed are methods of preparing an isolated population of human papillomavirus (HPV)-specific T cells comprise dividing an HPV-positive tumor sample into multiple fragments; separately culturing the multiple fragments; obtaining T cells from the cultured multiple fragments; testing the T cells for specific autologous HPV-positive tumor recognition; selecting the T cells that exhibit specific autologous HPV-positive tumor recognition; and expanding the number of selected T cells to produce a population of HPV-specific T cells for adoptive cell therapy. Related methods of treating or preventing cancer using the T cells are also disclosed.
    Type: Grant
    Filed: June 13, 2022
    Date of Patent: March 5, 2024
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • Patent number: 11915815
    Abstract: A computer-implemented system may include an electromechanical machine configured to be manipulated by a user while the user performs a treatment plan, an interface comprising a display configured to present information associated with the treatment plan, and a processing device configured to receive, from one or more data sources, information associated with the user, wherein the information comprises one or more risk factors associated with a cardiac condition or a cardiac outcome, generate, using one or more trained machine learning models, the treatment plan for the user, wherein the treatment plan is generated based on the information associated with the user, and the treatment plan comprises one or more exercises associated with managing the one or more risk factors in order to reduce a probability of a cardiac intervention for the user, and transmit the treatment plan to cause the electromechanical machine to implement the one or more exercises.
    Type: Grant
    Filed: March 10, 2023
    Date of Patent: February 27, 2024
    Assignee: ROM Technologies, Inc.
    Inventors: Joel Rosenberg, Jay L. Waddell, Steven Mason
  • Patent number: 11903966
    Abstract: Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: February 20, 2024
    Assignees: REGENTS OF THE UNIVERSITY OF MINNESOTA, INTIMA BIOSCIENCE, INC., The U.S.A., as represented by the Secretary, Department f Health and Human Services
    Inventors: Branden Moriarity, Beau Webber, Modassir Choudhry, Steven A. Rosenberg, Douglas C. Palmer, Nicholas P. Restifo
  • Patent number: 11897933
    Abstract: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: February 13, 2024
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Eric Tran, Yong-Chen Lu, Anna Pasetto, Paul F. Robbins, Steven A. Rosenberg, Zhili Zheng
  • Patent number: 11898207
    Abstract: Disclosed are methods of isolating paired T cell receptor (TCR) alpha and beta chain sequences, or an antigen-binding portion thereof. Also disclosed are methods of automatically identifying the TCR alpha and beta chain V segment sequences and CDR3 sequences of a TCR having antigenic specificity for a mutated amino acid sequence encoded by a cancer-specific mutation. Methods of preparing a population of cells that express paired TCR alpha and beta chain sequences, or an antigen-binding portion thereof, are also disclosed. Isolated pairs of TCR alpha and beta chain sequences and isolated populations of cells prepared by the methods are also disclosed.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: February 13, 2024
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Yong-Chen Lu, Peter Fitzgerald, Zhili Zheng, Steven A. Rosenberg
  • Patent number: 11879017
    Abstract: The invention provides chimeric antigen receptors (CARs) comprising an antigen binding domain of human antibody 139, an extracellular hinge domain, a transmembrane domain, and an intracellular domain T cell receptor signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are also disclosed.
    Type: Grant
    Filed: August 24, 2021
    Date of Patent: January 23, 2024
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Richard A Morgan, Steven A. Rosenberg
  • Publication number: 20240009243
    Abstract: Provided herein are methods for delaying or inhibiting T cell maturation or differentiation in vitro for a T cell therapy, comprising contacting one or more T cells from a subject in need of a T cell therapy with an AKT inhibitor and at least one of exogenous Interleukin-7 (IL-7) and exogenous Interleukin-15 (IL-15), wherein the resulting T cells exhibit delayed maturation or differentiation. In some embodiments, the method further comprises administering the one or more T cells to a subject in need of a T cell therapy.
    Type: Application
    Filed: June 26, 2023
    Publication date: January 11, 2024
    Inventors: Arianne PEREZ, Marianna SABATINO, Steven A. ROSENBERG, Nicholas P. RESTIFO
  • Publication number: 20230406904
    Abstract: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Application
    Filed: May 1, 2023
    Publication date: December 21, 2023
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Eric Tran, Yong-Chen Lu, Steven A. Rosenberg
  • Patent number: 11840561
    Abstract: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Grant
    Filed: December 3, 2021
    Date of Patent: December 12, 2023
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Eric Tran, Yong-Chen Lu, Anna Pasetto, Paul F. Robbins, Steven A. Rosenberg, Zhili Zheng
  • Publication number: 20230365649
    Abstract: Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated human RAS amino acid sequence with a substitution of glycine at position 13 with aspartic acid. The TCRs may recognize G13D RAS presented by an HLA-DQ heterodimer. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Application
    Filed: October 1, 2021
    Publication date: November 16, 2023
    Applicant: The USA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Noam Levin, Frank J. Lowery, III, Biman C. Paria, Steven A. Rosenberg, Rami Yoseph
  • Publication number: 20230340066
    Abstract: Disclosed is a T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E6, E629-38. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.
    Type: Application
    Filed: May 25, 2023
    Publication date: October 26, 2023
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • Publication number: 20230321240
    Abstract: Disclosed are isolated or purified T cell receptors (TCRs) having antigenic specificity for human p53R273C or human p53Y220C. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Application
    Filed: September 2, 2021
    Publication date: October 12, 2023
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Sanghyun Kim, Nikolaos Zacharakis, Steven A. Rosenberg
  • Patent number: 11779601
    Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes methods of identifying a patient who would respond well to a T cell therapy or conditioning a patient prior to a T cell therapy so that the patient responds well to a T cell therapy. The conditioning involves administering one or more preconditioning agents prior to a T cell therapy and identifying biomarker cytokines prior to administering a T cell therapy.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: October 10, 2023
    Assignees: Kite Pharma, Inc., The United States of America as represented by the Secretary, Department of Health and Human Services
    Inventors: Adrian Bot, Jeffrey S. Wiezorek, William Go, Rajul Jain, James N. Kochenderfer, Steven A. Rosenberg
  • Publication number: 20230303976
    Abstract: Disclosed are methods of isolating T cells and TCRs having antigenic specificity for a mutated amino acid sequence encoded by a cancer-specific mutation. Also disclosed are related methods of preparing a population of cells, populations of cells, TCRs, pharmaceutical compositions, and methods of treating or preventing cancer.
    Type: Application
    Filed: February 27, 2023
    Publication date: September 28, 2023
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Alena Gros, Steven A. Rosenberg
  • Publication number: 20230272038
    Abstract: Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated human RAS amino acid sequence with a substitution of glycine at position 12 with aspartic acid. The TCRs may recognize G12D RAS presented by an HLA-DR heterodimer. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Application
    Filed: July 13, 2021
    Publication date: August 31, 2023
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Noam Levin, Rami Yoseph, Gal Cafri, Steven A. Rosenberg
  • Patent number: D1017529
    Type: Grant
    Filed: August 17, 2023
    Date of Patent: March 12, 2024
    Assignee: Clearvue Technologies Ltd
    Inventors: Victor Rosenberg, Steven Coonen
  • Patent number: D1017530
    Type: Grant
    Filed: August 17, 2023
    Date of Patent: March 12, 2024
    Assignee: Clearvue Technologies Ltd
    Inventors: Victor Rosenberg, Steven Coonen